摘要
tepotinib是一种靶向间质-上皮转化(MET)的激酶抑制剂,于2021年2月3日获美国食品和药物管理局批准上市,用于治疗MET外显子14跳跃突变的转移性非小细胞肺癌成年患者。临床试验表明,tepotinib具有显著的抗肿瘤活性,常见不良反应为周围性水肿、腹泻及疲劳等,患者耐受性良好。
Tepotinib is a kinase inhibitor which has been approved by the U.S. Food and Drug Administration on February 3, 2021 for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymalepithelial transition(MET)exon 14 skipping alterations. Clinical trials have shown that tepotinib has significant antitumor activity. Common adverse reactions of tepotinib include peripheral edema, diarrhea, fatigue, etc. The patients were well tolerated.
作者
狄潘潘
DI Pan-pan(Pharmacy Intravenous Admixture Services,People's Hospital of Bozhou,Bozhou ANHUI 236800,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2022年第7期403-406,共4页
Chinese Journal of New Drugs and Clinical Remedies
